Current United States regulatory policies allow for the addition of pharmacologically active substances in dietary supplements if derived from a botanical source. The inclusion of certain nootropic drugs, such as vinpocetine, in dietary supplements has recently come under scrutiny due to the lack of defined dosage parameters and yet unproven short- and long-term benefits and risks to human health. This study quantified the concentration of vinpocetine in several commercially available dietary supplements and found that a highly variable range of 0.6–5.1 mg/serving was present across the tested products, with most products providing no specification of vinpocetine concentrations.
AvulaB., ChittiboyinaA.G., SagiS., WangY-H, WangM., KhanI.A., CohenP.A. (2015) Identification and quantification of vinpocetine and picamilon in dietary supplements sold in the United States. Drug Testing and Analysis, DOI: 10.1002/dta.1853.
4.
GoldmanP. (2001) Herbal medicines today and the roots of modern pharmacology. Annals of Internal Medicine, 135, 594–600.
5.
ShawD.M. (2012) Neuroenhancers, addiction and research ethics. Journal of Medical Ethics, 38, 605–608.
6.
NobleK.A. (2012) Brain gain: Adolescent use of stimulants for achievement. Journal of PeriAnesthesia Nursing, 27, 415–419.
7.
BhadraS., DasS.C., RoyS., ArefeenS., RoufA.S.S. (2011) Development and Validation of RP-HPLC Method for Quantitative Estimation of Vinpocetine in Pure and Pharmaceutical Dosage Forms. Chromatography Research International, 2011, 801656.
8.
JordanM.A., ThrowerD., WilsonL. (1991) Mechanism of inhibition of cell proliferation by Vinca alkaloids. Cancer Research, 51, 2212–2222.
9.
KruczynskiA., BarretJ-M, EtievantC., ColpaertF., FahyJ., HillB.T. (1998) Antimitotic and tubulin-interacting properties of vinflunine, a novel fluorinated Vinca alkaloid. Biochemical Pharmacology, 55, 635–648.
10.
SzatmariS., WhitehouseP. (2003) Vinpocetine for cognitive impairment and dementia. Cochrane Database of Systematic Reviews, 1, CD003119.
11.
NicholsonC.D. (1990) Pharmacology of nootropics and metabolically active compounds in relation to their use in dementia. Psychopharmacology, 101, 147–159.
12.
UmarT., HodaN. (2015) Selective Inhibitors of Phosphodiesterases: therapeutic promise for neurodegenerative disorders. MedChemComm, 16, 2063–2080.
13.
DeshmukhR., SharmaV., MehanS., SharmaN., BediK.L. (2009) Amelioration of intracerebroventricular streptozotocin induced cognitive dysfunction and oxidative stress by vinpocetine - a PDE1 inhibitor. European Journal of Pharmacology, 620, 49–56.
14.
MedinaA.E. (2010) Vinpocetine as a potent anti-inflammatory agent. Proceedings of the National Academy of Science, 107, 9921–9922.
15.
Ruiz-MiyazawaK.W., Pinho-RibeiroF.A., ZarpelonA.C., Staurengo-FerrariL., SilvaR.L., Alves-FilhoJ.C., CunhaT.M., CunhaF.Q., CasagrandeR., VerriW.A.Jr (2015) Vinpocetine reduces lipopolysaccharide-induced inflammatory pain and neutrophil recruitment in mice by targeting oxidative stress, cytokines and NF-κB. Chemico-Biological Interactions, 25, 9–17.
16.
MedinaA.E., KraheT.E., RamoaA.S. (2006) Restoration of neuronal plasticity by a phosphodiesterase type I inhibitor in a model of fetal alcohol exposure. Journal of Neuroscience, 26, 1057–1060.
17.
NunesF., Ferreira-RosaK., PereiraM.S., KubruslyR.C., ManhaesA.C., Abreu-VillacaY., FilgueirasC.C. (2011) Acute administration of vinpocetine, a phosphodiesterase type 1 inhibitor, ameliorates hyperactivity in a mice model of fetal alcohol spectrum disorder. Drug and Alcohol Dependence, 19, 81–87.
18.
GhoshR., SawantO., GanpathyP., PitreS., KadamV.J. (2009) Phosphodiesterase inhibitors: their role and implications. International Journal of PharmTech Research, 1, 1148–1160.
19.
FilgueirasC.C., KraheT.E., MedinaA.E. (2010) Phosphodiesterase type I inhibition improves learning in rats exposed to alcohol during the third trimester equivalent of human gestation. Neuroscience Letters, 473, 202–207.
